About Careers MedBlog Contact us

Aspirin Cuts Cancer Risk

by Sheela Philomena on April 1, 2013 at 10:26 AM
Font : A-A+

 Aspirin Cuts Cancer Risk

Low-dose aspirin could help decrease the risk of developing cancer by 25 percent, says study.

The findings of the study suggest that a low-dose pill can be taken to help keep cancer at bay, in the same way that aspirin is currently prescribed to protect against heart disease, the Daily Express reported.


Experts at Queen's University, Belfast, used information from the National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer trial for a large scale investigation of the effect of aspirin and ibuprofen on head and neck cancer risk.

They found that people were 22 percent more likely to avoid developing head and neck cancers if they took aspirin on a weekly and monthly basis.

The medicine pill, dubbed "wonderdrug," was most effective in throat cancer prevention.

For those aged 55-74, there was a "significant" reduction of head and neck cancer risk between weekly and monthly aspirin use.

The study has been published in the British Journal of Cancer.

Source: ANI


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Aspirin Cuts Cancer Risk Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests